Moderna Cuts Full-Year Revenue Guidance as COVID-19 Vaccine Sales Crater in Q2

Moderna’s stock price plunged more than 20% in Thursday morning trading after the company lowered its 2024 revenue guidance due to weak demand for its coronavirus vaccine in the second quarter.